The clinical utility of longitudinal measurement of mutated EGFR in plasma of advanced NSCLC patients during EGFR-TKI treatment
A. Szpechcinski (Warsaw, Poland), M. Bryl (Poznan, Poland), E. Wojda (Warsaw, Poland), G. Czyzewicz (Krakow, Poland), D. Swiniuch (Poznan, Poland), M. Szwiec (Zielona Gora, Poland), R. Ramlau (Poznan, Poland), P. Sliwinski (Warsaw, Poland), A. Barinow-Wojewodzki (Poznan, Poland), J. Chorostowska-Wynimko (Warsaw, Poland)
Source: International Congress 2022 – Translational research in COPD and lung cancer
Session: Translational research in COPD and lung cancer
Session type: Thematic Poster
Number: 4259
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Szpechcinski (Warsaw, Poland), M. Bryl (Poznan, Poland), E. Wojda (Warsaw, Poland), G. Czyzewicz (Krakow, Poland), D. Swiniuch (Poznan, Poland), M. Szwiec (Zielona Gora, Poland), R. Ramlau (Poznan, Poland), P. Sliwinski (Warsaw, Poland), A. Barinow-Wojewodzki (Poznan, Poland), J. Chorostowska-Wynimko (Warsaw, Poland). The clinical utility of longitudinal measurement of mutated EGFR in plasma of advanced NSCLC patients during EGFR-TKI treatment. 4259
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|